Background Emerging preclinical evidence indicates statins, medications commonly used in the prevention of cardiovascular disease (CVD), inhibit proliferation, promote apoptosis and limit invasiveness of esophageal adenocarcinoma (EAC). Population-based observational data demonstrate statin treatment after diagnosis of EAC is associated with significant reductions in all-cause and cancer-specific mortality. A feasibility study of adjuvant statin therapy following potentially curative resection for EAC has been completed, with planned progression to a full phase III, randomized controlled trial. Objective The aim was to estimate the cost-utility of statin therapy following surgical resection for EAC from a UK National Health Service (NHS) perspective. Methods A Markov model was developed to estimate the costs and outcomes [quality-adjusted life years (QALYs)] for hypothetical cohorts of patients with EAC exposed or not exposed to statins following potentially curative surgical resection. Model parameters were based on estimates from published observational and trial data. Costs, utilities and transition probabilities were modeled to reflect clinical practice from a payer's perspective. Probabilistic and one-way sensitivity analyses were performed to account for uncertainty in key parameters. Results Overall, a cost saving of £6781 per patient was realized with statin treatment compared to no statins. In probabilistic sensitivity analysis, 99% of all iterations were cost saving and 99% of all iterations were less than £20,000 per QALY gained. These results were robust to changes in the price and effectiveness of statins. Conclusions The cohort exposed to statins had lower costs and better QALY outcomes than the no statin cohort. Assuming a causal improvement in disease outcomes following resection for EAC, statin therapy is very likely to be a cost-saving treatment.
Epidemiological and trial data can be efficiently applied and drawn together within modeling studies to estimate the associated economic impact of treatments upon UK National Health Service (NHS) resources (i.e., the cost per quality-adjusted life year).
Assuming a causal improvement in survival postresection of esophageal adenocarcinoma (EAC), statin therapy is very likely to be a cost-effective treatment strategy.
The development of randomized controlled trials to establish the efficacy of statins as an adjuvant treatment for EAC is warranted from a clinical perspective.
Introduction
Esophageal cancer (EC) is the eighth most common cancer worldwide and is associated with a dismal prognosis [1] . In the United Kingdom (UK), there were 8784 newly registered cases in 2013 and 7701 deaths, ranking EC as the fourth and sixth cause of cancer death in men and women, respectively, in 2014 [2] . Within the Western world, esophageal adenocarcinoma (EAC) is the commonest histological subtype of esophageal malignancy [3] . Since the 1970s, the incidence of EAC has risen sixfold in England and Scotland, with the UK currently having the highest age-standardized incidence rate in the Western world [4, 5] . In 2012-2013, the cost of EC was estimated at £134 million, approximately 0.3% of total National Health Service (NHS) costs, and as the incidence continues to rise, the economic burden to NHS resources will increase [6] .
The mainstay of treatment in patients with potentially curable EAC is surgery with or without chemotherapy or chemo-radiotherapy [1] . Most recent trial data show that patients with esophageal and junctional adenocarcinomas treated with pre-operative chemo-radiotherapy have a 5-year survival of 45%, at best [7] , with most deaths attributable to recurrent disease.
There is currently a substantial research focus on the anti-cancer effects of statins [3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors], medications commonly prescribed for the prevention of primary and secondary cardiovascular disease [8] . There is growing experimental evidence to suggest statins promote apoptosis, inhibit proliferation and limit invasiveness in EAC cell lines [9] [10] [11] [12] . There is strong epidemiological evidence for statins reducing the risk of cancer-related mortality. The most recent systematic review and meta-analysis of observational studies included 95 cohorts with over 1.1 million cancer patients (from multiple sites) and demonstrated post-diagnosis statin use was associated with a significant reduction in all-cause mortality [hazard ratio (HR) 0.65, 95% confidence interval (CI) 0.60-0.72], with similar effect sizes for both cancer-specific mortality and disease-free survival (DFS) [13] . A population-based cohort study of 4445 patients with EC conducted in the UK, with linkage between the Clinical Practice Research Datalink (CPRD) (a large primary care database of anonymized medical records of over 11.3 million patients from over 560 UK general practices), the National Cancer Data Repository, and the Office for National Statistics Datasets, similarly demonstrated significant reductions in EC-specific mortality (HR 0.63, 95% CI 0.38-0.96) and all-cause mortality (HR 0.63, 95% CI 0.43-0.92) associated with statin use following diagnosis of EAC [14] . Statin use was modeled as a time-dependent exposure, adjusted for age, gender, body mass index, smoking status, cardiovascular disease, diabetes mellitus, surgery, chemotherapy, radiotherapy and medication use (aspirin, angiotensin-converting enzyme inhibitors, and angiotensin 2-receptor blockers, beta-blockers and nonsteroidal anti-inflammatory drugs). Based on the emerging experimental and observational data, the STAT-ROC feasibility study [15] has been completed to determine the prospect of investigating adjuvant statin therapy in the setting of prevention of recurrence of potentially curative EAC. The feasibility study was a multicenter, double-blind, parallel-group, randomized trial to estimate the recruitment, retention, drug adherence, and safety of statins, which strongly supports the feasibility of a future phase III, randomized controlled trial (RCT), which is currently in development.
In deciding patient care for the individual, delivery of service is influenced by the impact of care upon the individual's survival and quality of life. Additionally, the cost burden to the NHS is likely to affect the choice of treatment recommended by decision-makers. The National Institute for Health and Care Excellence (NICE) clinical guideline CG181 recommends [8] patients are treated with statins for primary and secondary prevention of cardiovascular disease at the NICE threshold value of £20,000 cost per QALY gained, but the 'value for money' of statins as an adjuvant treatment for EAC recurrence following potentially curative surgery is unknown.
In light of the economic burden upon NHS resources and emerging experimental and observational data surrounding statin treatment for patients post-diagnosis of EAC, we evaluated the cost-effectiveness of statin therapy following potentially curative resection (esophagectomy) for locally advanced EAC. Current UK practice, as reflected in a recent national audit, is either surgery alone or in combination with perioperative chemotherapy (used in[80%) [16] . We modeled, integrating observational and trial data, the potential for statin therapy to be cost-effective in terms of a cost per quality-adjusted life year (QALY) gained. The aim of this study was to determine the cost-effectiveness of statin therapy as an adjuvant treatment for EAC.
Methods
A probabilistic state-transition model was developed in Microsoft Excel 2013 (Microsoft Corporation, Redmond, WA, USA) to estimate the cumulative cost and QALY outcomes associated with exposure to statin use alongside standard care (surgery ± perioperative chemotherapy) versus no statin use with standard care only, in patients following surgical resection post-diagnosis of EAC. A UK NHS payer perspective was adopted, and following the NICE methods guide, costs and outcomes were discounted at 3.5% [17] .
Model Structure
The state-transition model consisted of three possible health states through which patients progressed. All patients began in the DFS state, following curative resection for EAC, and could transition to EAC recurrence and subsequently to death by EAC or death due to other causes (background mortality). Patients were also able to transition from DFS to death due to other causes, without transitioning to EAC recurrence. At entry into the model, patients in the statin arm were assumed statin users once daily and were at risk of statin-specific adverse events (AEs) within each health state. Patients in the non-statin arm received standard care only.
The model had a 1-year cycle length and a lifetime horizon (30 years, reflecting life expectancy in this population). A half-cycle correction was applied to the first cycle. Figure 1 presents the model structure.
Transition Probabilities and Key Model Assumptions
The baseline population was modeled to reflect the demographic characteristics of patients identified in the CPRD with a diagnosis of incident esophageal or esophagogastric junction cancers. The cohort from the CPRD had an average age of 71 years and 69% were male, which was the baseline population assumed within the model. To model the clinical efficacy, the baseline patient population was modeled to reflect data from the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) RCT. Briefly, the trial recruited 503 patients, predominately from the UK and Netherlands, to compare perioperative chemotherapy to no chemotherapy in patients with resectable gastroesophageal adenocarcinoma. This trial was selected since the active arm largely reflects current UK practice; most patients ([80%) treated with curative intent for EAC in the UK receive perioperative chemotherapy. A parametric function was fitted to the DFS curve observed in the perioperative chemotherapy arm to inform the baseline DFS in the model [18] . A Weibull distribution had the best fit to the observed data by the Kolmogorov-Smirnov statistic and Aikake's information criterion [19] [20] [21] and is illustrated in Fig. 2 . All patients were assumed eligible for statin therapy when they entered the model at baseline. The effect size for the association between post-diagnostic statin use and allcause mortality from UK observational data (HR 0.63, 95% CI 0.43-0.92) was assumed to approximate the effect size of statin use on DFS in the model [14] . Median adherence to statin therapy in the intended patient population from feasibility data is 91.5% [15] . To be conservative, in a sensitivity analysis, we assumed adherence to statins was 90%. The DFS benefit of statins was assumed to persist for as long as patients continued on treatment until recurrence or death. Reflecting clinical outcomes observed in the MAGIC trial [18] , patients in both arms of the model were assumed to be at risk of EAC recurrence for 6 years following successful resection, with no recurrences beyond 6 years. Patients who were non-statin users or withdrew from statin therapy because of an AE had the same risk of progression as patients in the no treatment arm, i.e., baseline DFS.
The risk of AEs as a result of statin use was modeled based on current clinical practice and literature [22, 23] . Where an AE attributed to statins occurred, patients were assumed to discontinue the drug. Finegold et al. [23] reported patients allocated to statin treatment versus placebo as having a statistically significantly higher risk of transaminitis [elevated transaminases alanine transaminase (ALT) and/or aspartate transaminase (AST) to greater than three times the upper limit of normal (ULN) [22] ] and type 2 diabetes mellitus (T2DM). The increased relative risks of transaminitis and of T2DM due to statins were reported as 31.5% and 24.7%, given an average follow-up of 3.19 years [23] . The rate of new incident cases was adjusted for the follow-up period reported and was assumed to persist over the lifetime patients remained in the model. Patients experiencing transaminitis were assumed to discontinue statins and reverted to the baseline risks of disease progression, whilst patients developing diabetes continued treatment. Allocation to statins is associated with large relative but low absolute risk of Disease-free survival
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Background Mortality EAC recurrence Fig. 1 The probabilistic state-transition model as a schematic of the possible health states patients progress through within each 1-year cycle over a lifetime horizon. All patients begin in the disease-free survival health state and can either remain in that state, have an EAC recurrence, or die due to background mortality or due to EAC. Once a patient progress' to EAC recurrence, the patient will continue to remain in that state or die due to EAC or due to other mortalities. EAC esophageal adenocarcinoma rhabdomyolysis (a severe form of myopathy characterized by muscle breakdown with myoglobin released into the systemic circulation) [22, 24] . Whilst statin-associated rhabdomyolysis events are rare, clinically, they are important as they would be expected to lead to discontinuation of treatment and, in severe cases, acute renal failure and death [25] [26] [27] . Given these potentially severe consequences, the risk of rhabdomyolysis was included in the model to take a conservative approach in considering the costs and outcomes of statin treatment. Furthermore, to assume a simplistic model approach, the effectiveness of statins in the primary and secondary prevention of cardiovascular disease [24, 28, 29] was not included in the model, to focus wholly on the benefits in the context of EC. Patients were also subject to an age-sex-specific risk of allcause mortality derived from UK national life tables [30] . Assuming a predicted mortality of 8.51 per 100,000 [31] , all-cause mortality was adjusted for potential double counting of EAC mortality. The parameter values used within the model are shown in Table 1 .
Costs
The costs of statin use against no treatment were modeled with reference to the effect size demonstrated in Alexandre et al.'s [14] population-based data from the perspective of the UK NHS healthcare system. All costs were inflated to 2016 prices using the Personal Social Services Research Unit (PSSRU) UK [32] hospital and community health services index. Where available, unit costs were drawn from the British National Formulary 71 [33] , NHS reference costs 2014/15 [34] and NICE technology assessment costing reports [35] .
The annual cost of statin treatment was calculated based on the price of a 28-day supply of each of the five statins (simvastatin, pravastatin, atorvastatin, rosuvastatin and fluvastatin) weighted by the proportion of patients using each formulation and multiplied to an annual cost (£2.62 9 365/28 = £34.15/year) [33] . In a sensitivity analysis, we tested using the single highest monthly price in place of the weighted average price (rosuvastatin £29.60/month, £387.03/year).
It was assumed that patients in a disease-free state following surgery would have follow-up clinic appointments with an upper gastrointestinal (GI) surgeon every 6 months in the first 2 years and then yearly in the following 3-5 years. The cost of an EAC recurrence was estimated from NHS reference costs 2014/15 [34] [Healthcare Resource Group (HRG) code in brackets] and included one multidisciplinary team meeting (CMDT_C), appropriate investigations [CT scan (RD20A), endoscopy (FZ57Z) and x-ray (DAPF)], and any recommended oncology treatment or best supportive care. Oncology treatment costs following a recurrence were estimated, assuming 25% of patients received treatment with chemotherapy, 30% radiotherapy, 1% chemo-radiotherapy, and 10% stent [36] . The remaining 34% were assumed to receive treatment only with best supportive care. Median survival following recurrence was assumed to be 4 months, based upon the clinical experience of an upper GI surgeon (M.L.), and was assumed to be the same in both groups. Costs at death were based on estimates from a Marie Curie national primary care audit of end-of-life care. Hospital inpatient and community care were estimated as £425 and £145 per day, and patients were assumed to have a median survival of 120 days [37] . The annual cost of T2DM was drawn from a study by Hex et al. [38] . This study was identified in a systematic review that sought to estimate the health economic cost of T2DM treatment estimates [39] . The costs of liver transaminitis and rhabdomyolysis were drawn accordingly from NHS reference costs 2014/15 [34] . The cost of rhabdomyolysis was calculated as a weighted average cost of resource use related to the severity of a rhabdomyolysis event (life threatening, hospitalization, death or disability) and the percentage of patients experiencing each during a rhabdomyolysis event.
Utilities
Utility estimates for the model health states and AEs were identified, where possible, from a literature search of systematic reviews relating to the patient event. Utility estimates assessed from the European Quality of Life-5 Dimension-3 Level (EQ-5D-3L) questionnaire, derived from UK time trade-off values, were preferred. ALT alanine transaminase, CI confidence interval, EAC esophageal adenocarcinoma, HR hazard ratio, PSA probabilistic sensitivity analysis, SD standard deviation, T2 Table 2 (data drawn from Table 2 in the source article), T3 ALT alanine transaminase, BNF British National Formulary, EAC esophageal adenocarcinoma, HRG Healthcare Resource Group, NHS National Health Service, PSA probabilistic sensitivity analysis, TA technology assessment, ULN upper limit of normal a Liver transaminases occurs when the transaminases is greater than 3 times the ULN The baseline utility estimate for patients in the DFS state was based on the baseline EQ-5D-3L data of 41 patients undergoing esophagostomy or total gastrectomy, entering a RCT feasibility study. Mean utility was estimated using UK time trade-off values, and was assumed from the study in the model as 0.80 [40] . The utility of EAC recurrence was estimated by de Boer et al. [41] , using standard gamble techniques, from a cohort of 50 patients interviewed following esophagectomy for EAC, with an average age of 63 years.
Estimates of the utility of abnormal liver function tests were calculated by Donnan et al. [42] from a cohort of 99 UK patients answering the EQ-5D-3L questionnaire. The utility of T2DM was identified from a systematic review conducted reporting T2DM utilities for economic models [43] . The measures of utility from the systematic review were estimates obtained from the United Kingdom Diabetes Study (UKPDS) to measure the utilities of T2DM patients [44] . As no utility estimate of rhabdomyolysis was retrieved from the literature, in line with the assumptions drawn by Mitchell et al. [45] , it was assumed the utility value would be comparable to severe myopathy [46] . The disutility was drawn from Mitchell et al. [45] and is presented in Table 2 , along with a summary of all utilities included in the model.
Analyses Performed
The cost-effectiveness result was calculated in terms of expected costs and QALYs. If there was a dominant alternative associated with lower costs and equivalent or better QALY outcomes, this alternative would be highlighted, and no incremental cost-effectiveness ratio (ICER) would be presented. Only if one alternative was associated with better QALY outcomes and increased costs was the expected cost per QALY gained calculated, i.e., the ICER.
Uncertainty was incorporated into the model through one-way sensitivity analysis on the cost of statins, followup, EAC recurrence, and the expected DFS rate, with incremental cost and QALYs only being measured. An alternative scenario analysis on the risk, cost, and utility of rhabdomyolysis was estimated, as well as a scenario allowing for 25% non-adherence. Probabilistic sensitivity analysis (PSA) was performed by replacing base-case estimates for key parameters with probability distributions and sampling values from these distributions over 5000 iterations. The PSA was conducted with a normal distribution around the HR of statin therapy. Beta distributions were assumed around the probabilities of an AE occurring, and the associated utility values. A gamma distribution with a shape parameter of 1 was conducted on the costs associated with statin treatment and the costs associated with EAC recurrence and death. Uncertainty was reported in terms of 95% CIs around key outcomes and graphically with a cost-effectiveness acceptability curve (CEAC). We also reported the probabilities that a statin strategy was dominated (greater costs, worse QALY outcomes), cost saving (lower costs, equivalent or better QALY outcomes), or cost-effective relative to the NICE £20,000 threshold. Additionally, we reported the expected value of perfect information (EVPI) [47] . Finally, we estimated the net budget impact of statins for each 1000 patients treated.
Results

Base-Case Results
In the base-case analysis, statins appeared to be the dominant therapy and, therefore, a cost-saving treatment of £6781 (95% CI 12,471-1375) (see Table 3 ). Including the costs of treatment, statins led to greater costs per patient (£487) because of AEs and follow-up appointments. However, statins led to a decrease of £7268 in EAC recurrence costs. Lifetime expected QALYs per patient were 4.93 with statins and 3.25 without statins, representing a gain of 1.68 (95% CI 0.12-4.41) QALYs per patient prescribed statins. The budget impact analysis suggested net savings of £6.40 million (95% CI £12.47-1.38 million) for each 1000 EAC patients receiving statin therapy. With respect to recurrences and AEs, statins were associated 
Sensitivity Analysis
Consistent with the base-case results, the PSA suggested a 98.94% probability that statins were cost-effective relative to a £20,000 per QALY gained threshold, a 98.86% probability of being cost saving, and only a 0.36% probability that the statin alternative was dominated (more costly and less effective). These probabilistic results are illustrated in the scatter plot in Fig. 3 . One-way sensitivity analysis showed that substituting the highest cost statin was still associated with cost savings and QALY gains with statins (-£4545; 1.68 QALYs), and threshold analysis showed that a statin strategy would meet a £20,000 per QALY gained threshold at an annual statin cost of up to £6406 (£534 per month) or an HR as high as 0.99. Decreasing the modeled expected DFS curve of the benefit of statins (Fig. 2) by 50%, from 34 to 17%, improved cost savings and QALY gains (-£8659; 2.18 QALYs), whilst increasing it by 50%, from 34% to 51%, reduced savings and QALY gains (-£2151; 0.35 QALYs), but statins remained a dominant strategy under both scenarios. Where the cost of palliative care was halved, the cost saving result also decreased (-£3651; 1.68). Finally, a scenario analysis of doubling the cost of follow-up and halving the cost of EAC recurrence showed statins remained cost saving and led to QALY gains (-£6136; 1.68). An alternative scenario analysis of doubling the incidence, mortality, and the cost of rhabdomyolysis and halving its utility did not change the dominance of statins (-£6778; 1.68 QALYs). Allowing for non-adherence by assuming that 25% of patients did not take the drugs they received did not change the overall results. The results from the one-way sensitivity analyses are presented in Table 4 . We performed a number of validation checks consistent with the Assessment of the Validation Status of Health Economic (AdViSHE) decision models checklist [48] . The face validity of the conceptual model and input data were confirmed by a consultant upper gastro-intestinal surgeon and a gastroenterologist. Extreme values were tested against expected outcomes and check sums were used to trace the initial cohort through the model logic. The model structure was validated against a similar model of statins in chemoprevention in Barrett's esophagus [49] . Finally, the face validity of the final estimates, including costs and survival, was assessed by clinical experts.
To our knowledge, this is the only study presenting the results of the cost-effectiveness of statins alongside standard treatment following esophagectomy with curative intent for EAC. Given the 98.86% probability of the costsaving result and 98.94% probability of statins being costeffective in PSA, assuming causality, we believe the results we present are robust. This is supported by the sensitivity analyses that consistently showed that statins represented strong value for money across a range of assumptions and parameter values. In the absence of definitive evidence around the cost of follow-up and cost of recurrence, even when both were adjusted to double the parameter values, statins continued to remain cost saving. Additionally, the sensitivity analyses conducted also suggest that statins lead to gains in QALYs.
There are a number of limitations in the analysis. Firstly, we are aware the model did not include the related cardiovascular disease benefits due to statin exposure. As statins reduce mortality, the healthcare-related costs accrued due to additional life years should be modeled. Arguably, other conditions associated with advanced age, such as dementia and hip fracture are leading causes of mortality and may account for possible future medical costs that should also be modeled. As the aim of the costeffectiveness analysis was to inform on the efficacy of statin therapy in patients with EAC and to limit the scope to the condition of interest, we simplified the model to exclude the related cardiovascular disease benefits.
A second limitation is the assumption of the primary measure of benefit being informed from epidemiological population data [14] . While the roles of reverse causation bias and unmeasured confounding cannot be excluded, such observational research is the highest level of available evidence (there are no current trial data) on which to base this economic analysis. Even if the assumed effect size of statin therapy (HR = 0.63) is an overestimate, adjuvant statin therapy remains cost-effective assuming much lower estimates of effect size with statin treatment (i.e., HR = 0.99). In modeling the EAC mortality and all-cause mortality rates from observational data, we assumed the effect size of statins was applicable to patients following surgery for EAC and reflects the effect of statins on DFS. While the low EVPI of £3.07 suggests that there would be little value in refining the estimates of effect size from observational data alone, to change clinical practice and include the adjuvant treatment of EAC as a new licensed indication for statins would require a phase III RCT, hence, superseding the value of EVPI alone. The safety profile of statins is well described and favorable. However, factors other than EVPI, such as the clinical evidence of the disease area, are reported to have potential weight on recommendations for further research and should be carefully considered [50] .
Conclusions
Statin therapy for patients following potentially curative resection of EAC appears to reduce NHS cost, assuming there is a causal reduction in the risk of cancer recurrence and of death.
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